Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double blind, placebo controlled, randomised withdrawal phase 2a trial
BACKGROUND Current standard of care for trigeminal neuralgia is treatment with the sodium channel blockers carbamazepine and oxcarbazepine, which although effective are associated with poor tolerability and the need for titration. BIIB074, a Nav1.7 selective, state dependent sodium channel blocker, can be administered at therapeutic doses without titration, and has shown good tolerability in healthy individuals in phase 1 studies. We therefore assessed the safety and efficacy of BIIB074 in patients with trigeminal neuralgia in a phase 2a study. METHODS We did a double blind, multicentre, placebo controlled, randomised withdrawal phase 2a trial in 25 secondary care centres in Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, Romania, South Africa, Spain, Switzerland, and the UK. After a 7 day run in phase, eligible patients aged 18 80 years with confirmed trigeminal neuralgia received open label, BIIB074 150 mg three times per day, orally, for 21 days. Patients who met at least one response criteria were then randomly assigned (1:1) to BIIB074 or placebo for up to 28 days in a double blind phase. We used an interactive web response system to assign patients with a computer generated schedule, with stratification (presence or absence of existing pain medication) Patients, clinicians, and assessors were masked to treatment allocation. The primary endpoint was the difference between groups in the number of patients classified as treatment failure during the double blind phase assessed in the modified intention to treat population. We assessed safety in all patients who received one or more doses of BIIB074. This study is registered with ClinicalTrials.gov (NCT01540630) and EudraCT (2010 023963 16) FINDINGS The first patient was enrolled on April 23, 2012, and the last patient completed the study on February 26, 2014. We enrolled 67 patients into the open label phase; 44 completed open label treatment, and 29 were randomly assigned to double blind treatment (15 to BIIB074 and 14 to placebo) During the double blind phase, five (33% patients assigned to BIIB074 versus nine (64% assigned to placebo were classified as treatment failures (p=0*0974) BIIB074 was well tolerated, with similar adverse events in the double blind phase to placebo. Headache was the most common adverse event with BIIB074 in the open label phase (in 13 [19% of 67 patients) followed by dizziness (in six [9% patients) In the double blind phase, headache, pyrexia, nasopharyngitis, sleep disorder, and tremor were the most frequent adverse events in patients assigned to BIIB074 (in one [7% of 15 patients for each event) and headache, dizziness, diarrhoea, and vomiting were the most frequent adverse events in patients assigned to placebo (in one [7% of 14 patients for each event) No severe or serious adverse events were reported in the BIIB074 group during the double blind phase. One patient assigned to placebo reported intestinal adhesions with obstruction as a severe and serious adverse event, which was considered as unrelated to study medication. INTERPRETATION The primary endpoint of treatment failure was not significantly lower in the BIIB074 group than in the placebo group. However, our findings provide a basis for continued investigation of BIIB074 in patients with trigeminal neuralgia in future clinical trials. FUNDING Convergence Pharmaceuticals.
The Lancet Neurology